ロード中...
Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...
保存先:
主要な著者: | , , , , , , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
MDPI AG
2022-03-01
|
シリーズ: | Tomography |
主題: | |
オンライン・アクセス: | https://www.mdpi.com/2379-139X/8/2/57 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|